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Abstract 
Background: Polymorphisms in the gene for phosphatidylinositol binding clathrin assembly protein (PICALM), an 
endocytic-related protein, are associated with a small, increased risk of developing Alzheimer’s disease (AD), strongly 
suggesting that changes in endocytosis are involved in the aetiology of the disease. We have investigated the involve-
ment of PICALM in the processing of amyloid precursor protein (APP) to understand how PICALM could be linked 
to the development of AD. We used siRNA to deplete levels of PICALM, its isoforms and clathrin heavy chain in the 
human brain-derived H4 neuroglioma cell line that expresses endogenous levels of APP. We then used Western blot-
ting, ELISA and immunohistochemistry to detect intra- and extracellular protein levels of endocytic-related proteins, 
APP and APP metabolites including β-amyloid (Aβ). Levels of functional endocytosis were quantified using ALEXA 
488-conjugated transferrin and flow cytometry as a marker of clathrin-mediated endocytosis (CME).
Results: Following depletion of all the isoforms of PICALM by siRNA in H4 cells, levels of intracellular APP, intracel-
lular β-C-terminal fragment (β-CTF) and secreted sAPPβ (APP fragments produced by β-secretase cleavage) were 
significantly reduced but Aβ40 was not affected. Functional endocytosis was significantly reduced after both PICALM 
and clathrin depletion, highlighting the importance of PICALM in this process. However, depletion of clathrin did not 
affect APP but did reduce β-CTF levels. PICALM depletion altered the intracellular distribution of clathrin while clathrin 
reduction affected the subcellular pattern of PICALM labelling. Both PICALM and clathrin depletion reduced the 
expression of BACE1 mRNA and PICALM siRNA reduced protein levels. Individual depletion of PICALM isoforms 1 and 
2 did not affect APP levels while clathrin depletion had a differential effect on the isoforms, increasing isoform 1 while 
decreasing isoform 2 expression.
Conclusions: The depletion of PICALM in brain-derived cells has significant effects on the processing of APP, prob-
ably by reducing CME. In particular, it affects the production of β-CTF which is increasingly considered to be an 
important mediator in AD independent of Aβ. Thus a decrease in PICALM expression in the brain could be beneficial 
to slow or prevent the development of AD.
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Background
In 2009 Genome Wide Association Studies (GWAS) 
were published describing polymorphisms in a number 
of genes associated with an increased risk of develop-
ing Alzheimer’s disease (AD) including PICALM (phos-
phatidylinositol binding clathrin assembly protein) [1, 2]. 
PICALM is involved in clathrin-mediated endocytosis 
[3]. Subsequently, the large IGAP (International Genom-
ics of Alzheimer’s disease Project) study identified further 
genes encoding the endocytic proteins BIN1 (bridging 
integrator 1) and SORL1 (sortilin-related receptor) that 
reached genome-wide significance [2, 4, 5]. Pathway anal-
ysis of the IGAP study [4] identified a number of biologi-
cal pathways associated with AD including the regulation 
of endocytosis, thus emphasising the importance of this 
pathway in the pathogenesis of AD and suggesting areas 
for development of new therapies [3].
The amyloid cascade hypothesis is the leading theory 
to explain the aetiology of AD [6], suggesting that under-
standing how the production of β-amyloid (Aβ) from 
amyloid precursor protein (APP) is controlled should 
improve intervention strategies. After synthesis, some 
APP is transported via the secretory pathway to the cell 
surface and internalised by endocytosis for processing 
including cleavage by one of two routes [7, 8]. In the amy-
loidogenic pathway, β-secretase (identified as β-site APP 
cleaving enzyme or BACE1) cleaves APP to give two frag-
ments, sAPPβ and C99 [9–12]. The γ-secretase complex 
then cleaves C99 to produce Aβ and a C-terminal frag-
ment (CTF) [12–15]. The alternative non-amyloidogenic 
pathway involves cleavage of APP by α-secretase within 
the Aβ region to release sAPPα and precludes the forma-
tion of Aβ [16, 17]. It is thought that most amyloidogenic 
processing of APP occurs after endocytosis in the endo-
cytic/lysosomal system [18]. Endocytosis is thus central 
to the production of Aβ as it controls where APP is local-
ised in the cell and which enzymes it encounters [19].
Altered CME has been described previously in AD. 
Early endocytic changes (an increase in number and size 
of Rab5-positive endosomes) have been seen in post-
mortem AD brains [20, 21]. Inhibition of CME in vivo in 
APP transgenic mice and dynamin-dependent endocyto-
sis in vitro lowered Aβ levels [22, 23], while upregulation 
of endocytosis increased APP metabolism and Aβ secre-
tion [18]. Therefore endocytosis is strongly implicated in 
AD pathogenic processes.
PICALM is involved in the recruitment of clathrin and 
other proteins to the membrane and thus regulates the 
formation of clathrin-coated pits and vesicles in CME 
[24]; though how it might be involved in endocytosis in 
AD remains unclear. However, subjects carrying the AD 
risk alleles in PICALM and Clusterin show significantly 
poorer episodic memory, a marker for AD onset [25]. 
In yeast, deletion of PICALM homologues protected 
against Aβ-induced toxicity [26]. In contrast, the pres-
ence of PICALM protective alleles appeared to be asso-
ciated with an increase in PICALM mRNA expression 
in human brain [27] and to protect against senile plaque 
development [28]. Decreased PICALM expression has 
been noted in AD brains along with abnormal cleavage 
fragments of PICALM and the association of PICALM 
with neurofibrillary tangles [29]. Thus PICALM may play 
an important role in AD, but the mechanism by which it 
does this is unclear. Since the processing of APP to Aβ 
is dependent on CME, our study aimed to investigate the 
contribution of PICALM to modulating the metabolism 
of APP and whether endocytotic processes were involved 
in that modulation.
We used the human brain-derived H4 neuroglioma 
cell line that expresses endogenous levels of APP as we 
wanted to look at the effects of PICALM on physiologi-
cally relevant levels of APP, more relevant to the situ-
ation found in AD patients. We found that these cells 
expressed PICALM isoforms 1 and 2. Having depleted 
levels of PICALM by siRNA targeting all four isoforms, 
we showed that the levels of intracellular APP, the intra-
cellular β-C-terminal fragment (β-CTF) and secreted 
sAPPβ (APP fragments produced by β-secretase cleav-
age) were significantly reduced but Aβ40 itself was 
not affected. Functional CME measured by transferrin 
uptake was significantly reduced after both depletion of 
PICALM and clathrin heavy chain (CHC). In contrast, 
depletion of clathrin did not affect APP levels but did 
reduce those of β-CTF. PICALM depletion altered the 
intracellular distribution of clathrin with less staining 
found in the perinuclear transgolgi region while clathrin 
depletion affected the subcellular pattern of PICALM 
labelling. Both PICALM and clathrin depletion reduced 
the expression of BACE1 mRNA and PICALM siRNA 
reduced protein levels. In contrast to the findings for 
depletion of all PICALM isoforms, individual depletion 
of PICALM isoforms 1 and 2 by specific siRNAs did not 
affect APP levels. Clathrin depletion had a more compli-
cated differential effect on the isoforms, increasing iso-
form 1 protein and mRNA expression while decreasing 
isoform 2 protein expression but not affecting mRNA 
levels.
Results
Effects of siRNA to total PICALM on PICALM mRNA 
and protein expression
In H4 cells, we detected two bands for PICALM 
using Western blotting with molecular masses of 
72.2 ±  0.4 and 65.8 ±  0.9 kDa (Fig. 1a). Four main iso-
forms (isoforms 1–4) of PICALM have been identi-
fied [30] [NCBI RefSeq:NP_009097.2, NP_001008660.1, 
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NP_001193875.1, and NP_001193876.1, respectively]. 
It is likely that the 72.2  kDa band equates to isoform 1 
[NCBI RefSeq:NP_009097.2] with a predicted mass 
of 70.6 kDa and the 65.8 kDa band to isoform 2 [NCBI 
RefSeq:NP_001008660.1] with a predicted mass of 
66.3  kDa. We saw no evidence of bands with a pre-
dicted mass of 69.9  kDa or 59.9  kDa, equating to iso-
forms 3 [NCBI RefSeq:NP_001193875.1] and 4 [NCBI 
RefSeq:NP_001193876.1], respectively, in our cells.
Using an siRNA sequence directed against all the iso-
forms of PICALM (Seq. A), we significantly reduced the 
total levels of PICALM to 17.9 ± 6.2 % of levels in control 
cells incubated with siRNA to GFP where PICALM lev-
els were unaffected (Fig. 1b). In parallel, PICALM mRNA 
levels were reduced to 16.3 ± 1.8 % of those in GFP con-
trol siRNA cells (Fig. 1c). In immunocytochemistry, total 
PICALM depletion greatly reduced the marked punc-
tate cytoplasmic and membrane-associated staining for 
PICALM seen in GFP control cells (Fig. 2a, b). There was 
no apparent perinuclear labelling seen for PICALM in 
GFP control cells (Fig. 2a).
siRNA to PICALM did not have any significant effect 
on cell viability measured using the MTS assay with 
absorbance levels of 98  ±  4.6 and 91.4  ±  2.3  % of the 
media control after treatment with siRNA to GFP and 
PICALM, respectively. There was also no significant 
difference in mean cell numbers as a percentage of the 
media control after treatment with siRNA targeting 
PICALM (56.2 ±  15.4  %) compared to mean cell num-
bers following treatment with siRNA targeting GFP 
(82.0 ± 8.2).
Effects of siRNA to total PICALM on endocytosis
Having demonstrated an extensive reduction in the 
levels of PICALM, we investigated whether other pro-
teins involved in CME were affected by siRNA to 
PICALM. Figure 3 shows that neither levels of CHC nor 
dynamin II were significantly affected by the reduction 
in PICALM levels. In addition, siRNA to PICALM had 
no significant effect on CHC mRNA with a reduction 
in mRNA levels for CHC to 98.2 ±  17.5  % of those in 
GFP control siRNA cells (data not shown). However, 
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Fig. 1 PICALM levels in H4 cells following siRNA treatments. a Representative immunoblot of PICALM after transfecting H4 cells for 48 h with 
control siRNA (GFP siRNA) or siRNA targeting PICALM (PICALM siRNA) and b following densitometric analysis. Data are presented as mean ± SEM as 
a percentage of the untreated media control after normalisation to house-keeping protein levels, n = 8, ***p < 0.001 significantly different to GFP 
siRNA with an unpaired Student’s t test. c PICALM mRNA expression levels using quantitative PCR, normalised to the housekeeping gene 18S and 
relative to the untreated cells. Data are presented as mean ± SEM, n = 6, **p < 0.01 significantly different to GFP siRNA with Mann–Whitney-U
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although clathrin levels overall were unaltered, we did 
see a reduction in the labelling for clathrin in the peri-
nuclear region of cells depleted of PICALM compared 
to control cells, probably representing the transgolgi 
network (Fig.  2d, e). Furthermore, depletion of total 
PICALM significantly reduced the uptake of transferrin 
GFP siRNA PICALM siRNA Clathrin siRNA
PICALM
BACE1
APP
Clathrin
g ih
d fe
a cb
j lk
Fig. 2 PICALM (a–c), clathrin (d–f), APP (g–i) and BACE1 (j–l) localisation after different siRNA treatments. H4 cells were incubated for 48 h with 
control siRNA (GFP siRNA, a, d, g, j), siRNA targeting PICALM (PICALM siRNA, b, e, h, k) or clathrin heavy chain (Clathrin siRNA, c, f, i, l). Proteins were 
detected using a biotinylated secondary antibody and an FITC-conjugated avidin construct (green), nuclei are counterstained with DAPI (blue). 
Images were taken with a Leica SP5 confocal laser scanning microscope and are representative from n = 3 (scale bar 25 μm). Arrows indicate the 
reduced cytoplasmic and membrane-associated staining seen after treatment with PICALM siRNA (a) compared to GFP siRNA (b)
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to 75.9 ± 2.7 and 71.2 ± 1.7 % of GFP levels after 15 and 
30 min, respectively (Fig. 4).
Effects of siRNA to total PICALM on the metabolism of APP
siRNA to total PICALM significantly reduced the expres-
sion of APP to 73.3 ± 3.4 % of the GFP control levels in 
H4 cells (Fig. 5a). We repeated the experiment looking at 
APP levels using a different, but equally effective, siRNA 
to PICALM (Seq. B) which reduced PICALM levels to 
8.2 ± 4.4 % of GFP control levels. This siRNA had a simi-
lar effect on APP expression, reducing it to 85.9 ± 4.2 % 
of GFP levels (Fig.  5b). Reduced levels of APP protein 
after PICALM siRNA were also seen by immunocyto-
chemistry in H4 cells but the distribution of intracellular 
APP did not appear to be affected (Fig. 2g, h). However, 
the levels of Aβ40 were not affected by PICALM deple-
tion (Fig. 5c). Aβ42 could not be measured in the H4 cells 
as the levels were below the detection limits of ELISAs 
(data not shown). Further investigation of the fragments 
of APP found that sAPPα was unaffected by reducing 
PICALM expression (data not shown). In contrast, the 
proportion of sAPPβ to sAPPα (expressed as a percent-
age) was significantly reduced by total PICALM siRNA to 
59.5 ± 7.2 % of GFP control levels (Fig. 5d). βCTF levels 
were significantly reduced to 52.7 ± 7.8 % of GFP levels 
(Fig. 5e). In contrast to the effect on protein expression, 
mRNA levels for APP were unaffected by treatment with 
siRNA to PICALM compared to GFP (Fig. 5f ). However, 
PICALM siRNA significantly reduced the amount of 
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Fig. 3 Clathrin and dynamin II protein expression levels following siRNA treatments. a Representative immunoblots of clathrin and dynamin II after 
incubating H4 cells for 48 h with media, control siRNA (GFP siRNA) or siRNA targeting PICALM (PICALM siRNA), b densitometric analysis of clathrin, 
n = 6 and c densitometric analysis of dynamin II, n = 4. Data are presented as mean ± SEM as a percentage of the untreated media control after 
normalisation to house-keeping protein levels
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Fig. 4 Effect of PICALM siRNA on clathrin-mediated endocytosis. H4 
cells were incubated with either control siRNA (GFP siRNA) or siRNA 
targeting PICALM (PICALM siRNA) prior to incubation with 100 nM 
Alexa488-Tf for 5, 15 or 30 minutes then trypsinised and analysed by 
flow cytometry. Mean fluorescent intensity data for the uptake of 
Alexa488-Tf are expressed as fold change over untreated control cells 
(0 min Alexa488-Tf ) and are mean ± SEM, ***p < 0.001, **p < 0.01 
significantly different to GFP siRNA with an unpaired Student’s t test, 
n = 3
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BACE1 mRNA compared to GFP siRNA to 80.5 ± 6.3 % 
(Fig. 5g). There was also a significant decrease in BACE1 
protein levels to 57.6 ± 2.9 % of GFP levels as measured 
by ELISA following treatment with PICALM siRNA 
(Fig. 5h). However, no apparent differences were detect-
able in the amount or distribution of staining for BACE1 
after PICALM depletion (β-secretase, Fig. 2j, k).
Association of PICALM GWAS SNPs with PICALM isoform 
expression
Using the Gibbs et  al. [31] eQTL dataset (150 healthy 
brains) and the UK Brain Expression Consortium eQTL 
dataset [32] (134 healthy brains) we found that the risk 
(major, G) allele of the most significant SNP in PICALM 
rs3851179 [2], and the risk allele (major, G) of the most 
significant SNP in PICALM from IGAP rs10792832 
[4], are both associated with a significant decrease in 
PICALM isoform 2 mRNA expression in the fron-
tal (rs10792832 p  =  0.029; rs38581179 p  =  0.022) and 
temporal cortex (rs10792832 p  =  0.019; rs38581179 
p  =  0.014) and the medulla from the Trabzuni data-
set [32] (rs3851179 and rs10792832 p  =  0.011). How-
ever, there was no significant change in the expression 
of PICALM isoform 1 mRNA associated with either 
rs3851179 or rs10792832.
Effects of siRNA to PICALM isoforms on PICALM mRNA 
and protein expression
Given that the PICALM SNPs were associated with dif-
ferential changes in the expression of the isoforms of 
PICALM, we examined the contribution of the isoforms 
of PICALM to its functions in endocytosis and potential 
involvement with the processing of APP. We designed 
siRNA to the two most abundant isoforms we identified 
in the H4 cells, isoforms 1 and 2. Figure 6a, b shows that 
an siRNA to isoform 1 significantly depleted the expres-
sion of this isoform to 19.3 ± 8.6 % of GFP levels, with-
out significantly affecting isoform 2. It was very difficult 
to design an siRNA for isoform 2 which did not have a 
significant effect on isoform 1 because of their overlap-
ping sequences and the most selective siRNA for isoform 
2 produced a smaller significant reduction to 48.2 ± 9.0 
of GFP levels, without affecting isoform 1 (Fig.  6a, c). 
mRNA for isoforms 1 and 2 were both significantly 
reduced to 20.7 ± 2.3 and 23.8 ± 1.9, respectively, from 
GFP levels by siRNA to total PICALM (Fig. 6d, e).
Effects of siRNA to isoforms 1 and 2 of PICALM on the 
metabolism of APP
In contrast to the siRNA to total PICALM which sig-
nificantly reduced APP levels, neither siRNA to isoform 
1 nor isoform 2 significantly affected the levels of APP 
(Fig.  7a). Similarly, only the siRNA to total PICALM 
significantly reduced the cleavage of APP to the βCTF 
fragment with the siRNA to isoforms 1 and 2 having no 
significant effect (Fig. 7b).
Effects of siRNA to clathrin heavy chain on endocytosis 
and APP expression
Having shown that depletion of PICALM affected func-
tional endocytosis, clathrin localisation and APP pro-
cessing, we examined whether knocking down clathrin 
itself would have any effect on PICALM or APP pro-
cessing. Using siRNA to CHC and compared to GFP 
siRNA-treated control cells, we significantly reduced 
the expression of CHC protein to 14.9 ± 1.5 % (Fig. 8a, 
b), CHC mRNA to 17.3  ±  3.9  % (Fig.  8c) and greatly 
reduced cell staining for clathrin (Fig. 2f ). This reduction 
in clathrin produced concomitant significant decreases 
in CME to 81.9  ±  7.4, 75.9  ±  2.7 and 71.2  ±  6.4  % of 
GFP levels after 5, 15 and 30 min, respectively (Fig. 8d). 
siRNA to CHC had no effect at all on the mRNA for 
total PICALM (data not shown). It did not significantly 
affect the total amount of PICALM at the protein level 
but did differentially affect the expression of isoforms 1 
and 2 of PICALM, resulting in a significant decrease in 
isoform 2 expression to 38.5 ± 9.2 % of GFP control lev-
els (Fig. 9a, c). There was also a concomitant increase in 
isoform 1 but this did not reach significance (Fig. 9a, b). 
At the mRNA level siRNA to CHC significantly increased 
isoform 1 mRNA to 426.4 ± 61.5 % (Fig. 6c) but had no 
significant effect on isoform 2 mRNA (Fig. 6d). Following 
siRNA to CHC, labelling for PICALM was altered with 
more pronounced staining seen in the cytoplasm and less 
(See figure on previous page.) 
Fig. 5 Effects of PICALM and clathrin siRNA on APP processing. H4 cells were incubated with media, control siRNA (GFP siRNA), siRNA targeting 
PICALM (PICALM siRNA sequence A or B) or clathrin heavy chain (Clathrin siRNA) for 48 h. Levels of APP after treatment with (a, PICALM siRNA 
Seq A) and (b, PICALM siRNA Seq B), c Aβ40, d sAPPβ:sAPPα, e βCTF and h BACE1 as detected by ELISA. Data are expressed as % of media control 
(a–c, e, h) and are mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different to GFP siRNA with an unpaired Student’s t test, n = 11 (a), 
n = 4 (b), n = 5 (c) n = 4 (d), n = 7 (e), n = 4 (h). f APP and g BACE1 mRNA expression levels measured using quantitative PCR, normalised to the 
housekeeping gene POLR2A and relative to the untreated cells. Data are expressed as mean ± SEM, *p < 0.05 significantly different to GFP siRNA 
with one-way analysis of variance and Dunnett’s multiple comparison test n = 6. Unless specified, cells were treated with siRNA targeting PICALM 
sequence A
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at the membrane (Fig. 2c). However, unlike the effect of 
the decrease in PICALM on APP processing, this reduc-
tion in CHC expression did not significantly alter the lev-
els of APP (Fig. 9d) but did significantly reduce the levels 
of βCTF to 67.4 ± 4.5 % of GFP levels (Fig. 9e). Similarly 
to PICALM siRNA, mRNA levels for APP were unaf-
fected by CHC siRNA (Fig.  5f ) but BACE1 mRNA was 
significantly reduced by CHC siRNA to 79.6  ±  6.0  % 
(Fig. 5g). BACE1 protein levels measured by ELISA were 
not significantly altered by CHC siRNA (Fig.  9f ). The 
labelling for APP and BACE1 were not affected by siRNA 
to CHC (Fig. 2i, l).
Discussion
We have demonstrated that reducing the expression of 
PICALM or clathrin inhibits CME to a similar extent and 
reduces β-secretase-mediated cleavage of APP but only 
PICALM siRNA affects the levels of APP. Thus PICALM 
can influence the processing of APP via more than one 
route possibly contributing to its role as a risk factor for 
AD.
The gene for PICALM gives rise to a number of iso-
forms [27, 33–35] of which 4 appear to be the most com-
mon [30]. In the H4 cells we consistently found isoforms 
1 and 2 with apparent higher expression levels of isoform 
2 but did not detect isoforms 3 or 4. Therefore all further 
work concentrated on isoforms 1 and 2. A similar pat-
tern has been described by other authors with isoforms 
1 and 2 being the predominant forms [24, 34–37]. Our 
two different siRNA sequences (Seqs. A and B), directed 
against a region common to all four isoforms, consist-
ently demonstrated a large reduction in the expression 
of PICALM with no significant toxic effects from either 
measure. Thus our data suggest that the reduction was 
specific to PICALM and that PICALM is not critical for 
cell survival.
Reducing PICALM expression by siRNA significantly 
inhibited the uptake of transferrin by functional CME 
in the H4 cells suggesting that, in these cells, PICALM is 
essential for normal levels of CME to occur, probably due 
to its involvement in the formation of clathrin-coated 
vesicles [24, 35]. These data agree with other findings on 
functional CME where reducing [24, 38, 39] or increasing 
[35, 38] the expression of PICALM resulted in changes 
in transferrin uptake. Other studies have described no 
effect of siRNA for PICALM on transferrin uptake [37, 
40, 41] but all these studies only measured endocytosis at 
short time intervals of 5–10 min so would not have seen 
effects occurring up to 30  min. Furthermore, this study 
used a quantitative assay in living cells unlike some other 
papers. It is also, however, possible that these findings 
could be explained by certain cells being capable of over-
coming PICALM depletion by increased reliance on its 
homologue, AP180 [24, 33].
The consequent decrease in functional endocytosis 
following PICALM depletion does not involve dynamin 
(See figure on previous page.) 
Fig. 6 PICALM levels following siRNA treatments targeting isoforms 1 and 2 of PICALM, total PICALM and clathrin. a Representative immunoblots 
of PICALM isoforms after incubating H4 cells for 48 h with media or siRNA targeting either total PICALM (sequence A), PICALM isoform 1, PICALM 
isoform 2, clathrin or GFP for 48 h. b Densitometric Western blot analysis of the levels of PICALM, isoform 1 and c isoform 2. Data are presented 
as a percentage of the untreated media control after normalisation to house-keeping protein levels and are mean ± SEM, n = 6–7, *p < 0.05, 
***p < 0.001 significantly different to GFP siRNA following one-way analysis of variance and Dunnett’s multiple comparison test (b) or Kruskal–Wal-
lis test and Dunn’s multiple comparison test (c). d PICALM isoform 1 and e PICALM isoform 2 mRNA expression levels measured using quantitative 
PCR, normalised to the housekeeping gene POLR2A and relative to the untreated cells, n = 5–6, ***p < 0.001 significantly different to GFP siRNA 
following one-way analysis of variance and Dunnett’s multiple comparison test
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Fig. 7 Effects of PICALM siRNA targeting isoforms 1 and 2 of PICALM 
on APP processing. Levels of a APP and b βCTF in H4 cells, as 
detected by ELISA following incubation with media, or siRNA target-
ing either total PICALM (sequence A), PICALM isoform 1, PICALM 
isoform 2 or GFP for 48 h. Data are expressed as % of media control 
and are mean ± SEM, *p < 0.01, ***p < 0.001 significantly different to 
GFP siRNA with a one-way analysis of variance and Dunnett’s multiple 
comparison test, n = 5 (a) and, n = 4–5 (b)
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or a change in the levels of clathrin since neither mRNA 
nor protein levels for CHC were altered by knockdown 
of PICALM. However, the localisation of clathrin in the 
transgolgi network was reduced by PICALM depletion 
possibly due to redistribution in the cell since overall 
protein expression was unaltered. A reduction in clathrin 
expression in the transgolgi network has been described 
previously for both decreasing [24] and increasing [35] 
the expression of PICALM, suggesting that PICALM is 
important for the correct localisation of clathrin in the 
cell. PICALM itself was not present in the perinuclear 
region, confirming previous findings [24, 35], so it is most 
likely to have an indirect effect on the targeting of clathrin 
to different subcellular areas. The control of trafficking 
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Fig. 8 Effects of clathrin siRNA on clathrin-mediated endocytosis. H4 cells were incubated with media, control siRNA (GFP siRNA) or siRNA targeting 
clathrin heavy chain (Clathrin siRNA) for 48 h. a Representative immunoblot of clathrin expression and b following densitometric analysis. Data 
are presented as a percentage of the untreated media control after normalisation to house-keeping protein levels and are mean ± SEM, n = 3, 
*p < 0.05 significantly different to GFP siRNA with an unpaired Student’s t test. c Clathrin mRNA expression levels using quantitative PCR, normalised 
to the housekeeping gene 18S and relative to the untreated cells. Data are presented as mean ± SEM, n = 6, **p < 0.01 significantly different to GFP 
siRNA with Mann–Whitney-U. d H4 cells were incubated with 100 nM Alexa488-Tf for 5, 15 or 30, minutes then trypsinised and analysed by flow 
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between the early endosome and the transgolgi network 
involves many proteins so depletion of PICALM could 
affect multiple targets [42]. PICALM is very important 
for controlling the endocytosis of R-SNAREs (Soluble 
NSF Attachment Protein Receptors) such as VAMP2, 
3 and 8 which are necessary for the fusion of endocytic 
vesicles containing various cargoes with endosomes 
or the plasma membrane for recycling [43]. VAMP3 
is also involved with the tethering of endosomes to the 
transgolgi network [42] so affecting VAMP3 function by 
depleting PICALM could reduce the amount of clath-
rin in the transGolgi network. Depleting cells of clathrin 
using siRNA to clathrin heavy chain significantly reduced 
transferrin uptake as expected [44]. Interestingly, we 
saw a different time course for depletion of clathrin or 
PICALM to affect significantly the uptake of transferrin. 
Al Soraj and co-workers [44] found the largest effect of 
clathrin depletion was at early time points and suggested 
that, at later time points, the effect of reduced recycling 
of transferrin from endosomes became more important. 
Thus the effects of PICALM depletion may be affected 
less by recycling from endosomes.
Consistent with previous findings showing that APP 
is internalised by endocytosis [45] and that PICALM 
is involved in this process [41], we saw a decrease in 
the expression of intracellular APP after depletion 
of PICALM. The specificity of this effect on APP to 
PICALM was confirmed using a second total PICALM 
siRNA sequence. Xiao et al. [41] did not see an effect on 
full-length APP after depletion of PICALM possibly due 
to their use of cells overexpressing APP where normal 
physiological mechanisms might be affected. However, 
the consequence of depleting PICALM on APP levels 
is additional to an effect on the formation of clathrin-
coated vesicles as reducing clathrin did not affect APP 
levels. PICALM can affect transcription [46], but the lev-
els of APP mRNA were not altered by depleting PICALM 
so the change in APP is very unlikely to be due to 
reduced protein synthesis. It was also not due to a change 
in the subcellular location of APP in our cells. It is there-
fore more likely that this reduction in APP is due to the 
disruption of R-SNARE proteins by PICALM depletion. 
Changes in VAMP3 and VAMP 8 have been postulated 
to explain the increased levels of total cellular choles-
terol seen after PICALM knockdown [47]. It is possible 
that the alterations in APP we see after PICALM siRNA 
could also be partly due to changes in cellular cholesterol 
homeostasis.
Depleting PICALM expression decreased β-secretase 
cleavage of APP as the levels of βCTF were reduced and a 
decrease in the sAPPβ/sAPPα ratio was seen. α-secretase 
activity was unaffected by depletion of PICALM. A 
role for PICALM in targeting CTF fragments of APP 
for degradation by autophagy has been suggested [48]. 
Thus an increase in β-CTF levels would be expected 
if PICALM levels are reduced but we saw the reverse. 
Therefore the decrease in β-CTF levels must occur 
upstream of autophagic processes, most likely via an 
effect on β-secretase. Although β-secretase cleavage was 
affected by knockdown of PICALM, the levels of Aβ40 
were unaffected agreeing with other studies [39, 41, 49, 
50]. βCTF is very likely to be involved in the development 
of the enlarged endosomes seen in both AD and Down 
Syndrome [51, 52]. βCTF is thought to activate rab5 via 
APPL1 (adaptor protein containing pleckstrin homol-
ogy domain, phosphotyrosine binding domain and leu-
cine zipper motif ) [52] leading eventually to endosomal 
enlargement [52, 53]. βCTF may thus have an important 
role in the pathogenesis of AD [52, 53] and therefore 
decreasing PICALM expression would be protective by 
lowering βCTF production. The decrease in βCTF we see 
is likely to be due in part to the reduction in endocytosis 
produced by PICALM depletion decreasing the entry of 
APP into the cells as it was also seen after knock down 
of clathrin. However, the effect of PICALM depletion on 
βCTF was greater than that produced by clathrin, pro-
viding further support for an effect of PICALM on APP 
independent of CME.
Previous work has shown that PICALM affects the 
endocytosis of γ-secretase and this was proposed to 
explain the effects of depletion of PICALM on Aβ genera-
tion [49]. However, we have clearly demonstrated here an 
effect on the cleavage of APP by β-secretase after deple-
tion of PICALM probably due to less APP being endo-
cytosed into early endosomes to encounter β-secretase. 
There was no apparent effect on the distribution of 
BACE1 in PICALM-depleted cells compared to con-
trol cells. Both PICALM and clathrin depletion reduced 
the levels of BACE mRNA by about 20 % and PICALM 
depletion reduced protein levels by 44.45 % with a trend 
for a decrease of 39.5 % seen with CHC siRNA, suggest-
ing an effect on BACE synthesis. The reduction in BACE1 
levels is unlikely to be due to an effect on endocytosis 
as it was seen at the mRNA level and clathrin siRNA, 
which reduced functional endocytosis, did not affect 
BACE1 protein expression. However, this reduction in 
BACE1 levels is unlikely to explain the 35–60 % decrease 
in βCTF production obtained with PICALM and CHC 
depletion as a 50  % decrease in BACE1 levels in trans-
genic BACE1 ± mice resulted in reductions in Aβ of no 
more than 12–40 % [54, 55]. Therefore it appears unlikely 
that a change in the levels of β-secretase itself is respon-
sible for the effects of PICALM and clathrin depletion on 
βCTF levels.
Having examined the effect of depletion of total 
PICALM on APP metabolism and, given that the 
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expression of isoform 1 was lower than isoform 2 in H4 
cells, we investigated whether the isoforms had differ-
ential effects on APP endocytosis and processing. We 
depleted isoform 1 and 2 individually using specific siR-
NAs which did not significantly affect the other isoform 
thus confirming that the two bands we saw in the H4 cells 
were indeed isoform 1 and 2. Interestingly, depletion of 
either isoform alone had no significant effect on the lev-
els of APP or βCTF so both PICALM isoforms must be 
involved in functional endocytosis in the H4 cells. How-
ever, the differential effect of clathrin depletion on the 
expression of the isoforms at both the mRNA and pro-
tein level does suggest that they may have different roles 
in CME. Clathrin depletion increased both the protein 
and mRNA for isoform 1 but decreased isoform 2 pro-
tein without altering the mRNA. The discrepancy for 
isoform 2 may be due to differences in mRNA stability 
between the two isoforms. The increase in one PICALM 
isoform and the decrease in the other may explain why 
clathrin depletion had no effect on APP levels. The intra-
cellular localisation of total PICALM was altered by clath-
rin depletion which could reflect differential changes in 
the expression of isoforms 1 and 2. We could not inves-
tigate this finding further to understand the mechanism 
involved as there are no commercial antibodies available 
which can distinguish between isoforms 1 and 2. Our 
findings from the eQTL data sets, showing an associa-
tion between a decrease in isoform 2 mRNA expression 
but no effects on isoform 1 mRNA for the Harold and co-
workers [2] and IGAP [4] SNPs, are interesting given that 
we and others find that control cells generally have higher 
levels of isoform 2 than isoform 1. These data suggest that 
the ratio of the two isoforms may be important physi-
ologically. However, given that we found that both iso-
forms needed to be knocked down to decrease APP and 
βCTF expression, it is currently unclear how the differ-
ential association of the GWAS PICALM SNPs with iso-
form expression are related to the processing of APP. Our 
data suggest that the relationship between PICALM and 
APP processing is likely to be highly complex and requires 
further investigation. There are very few published stud-
ies examining the biological effects of manipulating the 
isoforms of PICALM. Kanatsu and colleagues [39] looked 
at the effects of overexpressing isoforms 1 and 2 on Aβ 
secretion but did not see any differences. Other workers 
have shown reversal of the protective effect of depletion 
of PICALM yeast homologue isoforms 1 and 2 by mam-
malian isoform 2 (mammalian isoform 1 expression was 
toxic in yeast) [26]. Parikh et al. [27] examined the asso-
ciation of mRNAs for various splice variants of PICALM 
with a SNP encoding a polymorphism in the gene asso-
ciated with AD and found increased total PICALM 
expression correlated with the protective allele but there 
was no significant correlation with the splice variants.
Conclusions
In conclusion, we have demonstrated that the deple-
tion of PICALM in H4 cells has significant effects on 
the processing of APP, probably by reducing cleavage by 
β-secretase. The reduction in βCTF production is par-
ticularly interesting as this is now increasingly thought 
to have toxic effects on cells independent of Aβ. These 
effects are likely to be mediated by at least two processes, 
a reduction in CME and an alteration in the endocytosis 
of endocytic vesicles. Based on our data and on evidence 
from the literature, we hypothesise that polymorphisms 
of PICALM could alter the expression of the protein over 
the lifetime of an individual which would be associated 
with either an increased risk of developing AD or a pro-
tective effect. Further studies are required to elucidate the 
relative importance of these different roles of PICALM 
and the relevance of the isoforms to APP processing.
Methods
Materials
All chemicals and reagents were purchased from Sigma-
Aldrich, Poole, UK, Life Technologies (Invitrogen), 
Paisley, UK or Fisher Scientific, Leicester, UK and all 
reactions were performed at room temperature unless 
otherwise specified. All siRNA (sequences of 21–23 resi-
dues) were purchased from Eurofins Genomics, Ebers-
berg, Germany.
Antibodies were purchased as follows: Anti-APP 
(clone 22C11, MAB348, Millipore, Watford, UK), anti-
β-actin directly conjugated to horseradish peroxidase 
(HRP, clone AC-15, A3854) or GAPDH (clone GAPDH-
71.1, G9295, Sigma-Aldrich), anti-dynamin II (clone 27/
Dynamin II, 610263, BD Biosciences, Oxford, UK), anti-
clathrin heavy chain (clone 23/Clathrin Heavy Chain, 
Table 1 siRNA sequences used to  knock down  protein 
expression
a The siRNA sequences for total PICALM were directed against regions of the 
mRNA common to isoforms 1–4
siRNA target Sequence References
Total PICALM ‘A’a GCAUACAAUGAAGGAAUUAdTdT Custom-designed
Total PICALM ‘B’a AAGCCAAGAAUUGCUAUGAdTdT Custom-designed
PICALM isoform 1 GCAAGUACAUGGGGAGAUCdTdT Custom-designed
PICALM isoform 2 GUACAUGGGGAGGAUUCACdTdT Custom-designed
CHC UAAUCCAAUUCGAAGACC 
AAUdTdT
[43]
GFP GGCUACGUCCAGGAGCGCA 
CCdTdT
[43]
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610499, BD Biosciences), anti-PICALM (NBP1-86658, 
Novus Biologicals, Cambridge, UK), anti-BACE1 (clone 
M-83, sc-10748,Santa Cruz Biotechnology, Insight Bio-
technology, Wembley UK) and anti-rabbit (PI-1000) 
and anti-mouse (PI-2000) antibodies conjugated to HRP 
(Vector Laboratories, Peterborough, UK).
Cell culture
Neuroglioma H4 cells (ECACC, Porton Down, UK) were 
cultured in Opti-MEM media containing Glutamax (Inv-
itrogen) supplemented with 4  % foetal bovine serum 
(FBS, Perbio Science UK Ltd, Cramlington, UK).
Transfection of cells with siRNAs
The expression of PICALM and clathrin heavy chain 
(CHC) was depleted using siRNA as previously described 
[43]. Briefly, H4 cells were seeded in a 6 well plate at a 
density of 150,000 cells per well 24 h prior to treatment. 
All procedures were performed in Opti-MEM in the 
absence of serum. Complexes were pre-formed between 
the oligonucleotides and oligofectamine (Invitrogen) 
using 50  pmol oligonucleotide per 4  µl oligofectamine 
in a total volume of 200  µl Opti-MEM. The complex 
was subsequently added to cells to give a final oligonu-
cleotide concentration of 50 nM in a total of 1 ml Opti-
MEM. Cells were incubated with media, siRNA for green 
fluorescent protein (GFP) to control for off-target effects 
of oligofectamine and oligonucleotide, or the siRNA 
sequences in Table 1 for 4 h. 500 μl of Opti-MEM sup-
plemented with 12 % (v/v) FBS was then added directly 
to the transfection mixture and cells were then incubated 
for 48 h and processed as required.
Analysis of gene expression using quantitative PCR
After siRNA treatment cells were lysed in Trizol™ reagent 
(Invitrogen) then total RNA was extracted and purified 
using RQ1 RNase-Free DNase (Promega, Southampton, 
UK) followed by Qiagen RNeasy™ Mini kits (Qiagen, 
West Sussex, UK). cDNAs were synthesized from 800 ng 
RNA with SuperScript® First-Strand Synthesis System 
(Invitrogen) using Oligo(dT) and Superscript™ II reverse 
transcriptase. Real-time PCR was carried out on the 
LightCycler ® 2.0 Real-Time PCR System (Roche Diag-
nostics GmbH, Mannheim, Germany) using TaqMan 
gene expression assays (Table  2, Applied Biosystems, 
Paisley, UK) and LightCycler® TaqMan® Master hot start 
reaction mix (Roche). Reactions were carried out accord-
ing to the manufacturer’s protocols. Data were nor-
malised either to polymerase (RNA) II (DNA directed) 
polypeptide A (POLR2A) or 18S RNA levels. Relative 
quantification was calculated using the 2−ΔΔCt method 
[56] using media controls as a reference group to quan-
tify relative changes in target gene expression. Data are 
presented as fold change in expression normalised to the 
endogenous reference gene and relative to the untreated 
cDNA samples.
Western blotting
After siRNA treatment, cells were lysed as previously 
described [57] and total cell protein concentration was 
determined by bicinchoninic acid protein assay (Pierce, 
Rockford, IL, USA). Western Blotting was performed 
using standard methods. Briefly, samples were resolved 
on 10 % polyacrylamide gels, transferred on to 0.45 µm 
nitrocellulose membranes (Amersham Biosciences, Little 
Chalfont, UK), incubated with the relevant primary anti-
body and detected as previously described [57, 58].
Internalisation of Alexa‑488‑labelled transferrin as a 
measure of CME
This assay was performed according to Al-Soraj and co-
workers [43] as described below. siRNA-transfected cells 
were washed twice with Opti-MEM at room temperature 
and incubated with Opti-MEM containing 0.2  % (w/v) 
BSA for 30 min. Cells were then washed twice with Opti-
MEM at room temperature and incubated for 0–30 min 
with Opti-MEM containing 100  nM Alexa488-labelled 
transferrin (Alexa488-Tf; Life Technologies). Tissue cul-
ture plates were immediately placed on ice to inhibit 
further uptake and washed twice with ice-cold 0.1  M 
phosphate-buffered saline (PBS) followed by a 1  min 
incubation in ice-cold acid wash (0.2 M acetic acid, 0.2 M 
NaCl, pH 2.0) to remove remaining surface label. Cells 
were then washed three times with PBS at room temper-
ature and trypsinised. This reaction was inhibited with 
PBS supplemented with 1 % (w/v) BSA, trypsin inhibitor 
(1 mg/ml) and DNASE (75 µg/ml) before the cell suspen-
sion was washed with ice-cold PBS supplemented with 
1  % (w/v) BSA and DNASE (75  µg/ml). Cell-associated 
fluorescence was detected by flow cytometry on a BD 
Table 2 TaqMan probes used for  real-time quantification 
of genes following siRNA
All Taqman probes were purchased from Applied Biosystems
Gene Gene expression assay
Total PICALM Hs00200318_m1
PICALM isoform 1 Hs00999727_m1
PICALM isoform 2 Hs01003584_m1
PICALM isoform 3 Hs01008128_m1
CHC Hs00964504_m1
APP Hs00169098_m1
BACE1 (β-secretase) Hs01121195_m1
POLR2A Hs00172187_m1
18S Hs03928980_g1
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FACSCalibur™, BD FACSCanto™ or BD FACSVerse™ 
analyser (BD Biosciences, Oxford, UK). Cell debris and 
aggregates were gated out and 10,000 events counted. 
Data are expressed as fold change over control cells and 
the mean fluorescent intensity (MFI) is the geometric 
mean. Data were analysed with Cyflogic 1.2.1 (Cyflo LTD, 
Turku, Finland) or BD FACSuite™ software.
Quantification of APP
APP in the lysed cells samples was quantified using the 
APP DuoSet (R&D Systems, Abingdon, U.K.) following 
the manufacturer’s guidelines [57, 58]. Briefly, the capture 
antibody was used at 4  μg/ml in PBS overnight. Plates 
were blocked with 1 % bovine serum albumin (BSA) and 
5 % sucrose in PBS and samples were quantified using a 
six point standard curve. The biotinylated detection anti-
body was used at 300 ng/ml and detected using streptavi-
din-HRP and o-phenylenediamine.
Quantification of APP fragments: Aβ40, sAPPα, sAPPβ 
and βCTF
For analysis of Aβ40, media was subjected to immuno-
precipitation and ELISA as described previously [57, 58]. 
Briefly, the ELISA employed the N-terminal Aβ anti-
body 6E10 (5  mg/ml, Cambridge Bioscience Ltd, Cam-
bridge, UK), as the capture antibody and affinity-purified 
BAM401AP (0.45  μg/ml, Autogen Bioclear, Calne, UK), 
specific to the C-terminus of human Aβ40, as the detec-
tion antibody. To determine the effect of siRNAs on 
sAPPα and sAPPβ, media was tested in sandwich ELISAs 
(IBL, Hamburg, Germany) and intracellular βCTF levels 
were detected by ELISA (IBL).
Effect of siRNA to total PICALM on H4 cell viability
Viability studies were performed after incubation with 
siRNA to total PICALM for 48 and 72 h using the CellTi-
ter 96® MTS Aqueous One Solution Cell Proliferation 
Assay (Promega) following the manufacturer’s guide-
lines. The total number of cells was also counted using a 
Z™ Series Coulter Counter (Beckman Coulter (UK) Ltd, 
High Wycombe, UK).
Immunocytochemistry
H4 cells were plated on collagen-coated coverslips as pre-
viously described [57] and treated with various siRNA 
as described above for 48  h. H4 cells were then fixed 
and processed for immunocytochemistry as previously 
described [57, 59]. Cells were incubated with primary 
antibodies in blocking solution (PBS, 3 % serum from the 
species used to raise the secondary antibody, 1 % bovine 
serum albumin) overnight at 4 °C. Antibody labelling was 
detected using appropriate secondary antibodies con-
jugated to biotin (1:500, Vector Laboratories) followed 
by avidin-FITC (1:600, Vector Laboratories). Coverslips 
were mounted on to glass slides using VECTASHIELD® 
HardSet™ Mounting Medium (Vector Laboratories) 
with DAPI and visualized using a Leica SP5 confocal 
laser scanning microscope. GFP siRNA did not affect the 
localisation or expression of any of the proteins examined 
compared to media controls so the GFP siRNA images 
are shown for comparison with those obtained following 
siRNA for PICALM or clathrin.
Statistical analysis
Western blots were quantified using Image J, analysed as 
detailed previously [19] and expressed as relative density 
to the house keeping protein. Data generated in ELISA 
assays were quantified by comparing data to standard 
curves included on each plate using using Graphpad 
Prism® 5. Results were first normalised to total protein 
concentration, where relevant and expressed as % of 
media control values. Both sAPPβ and sAPPα were quan-
tified in ng/ml and then expressed as the ratio of sAPPβ 
to sAPPα. Where there were only two factors, data were 
compared to GFP using unpaired Student’s t tests, at the 
two-tailed significance level. Elsewhere data were ana-
lysed with one-way ANOVA followed by the relevant 
post hoc test comparing all data to GFP.
Where necessary, data were transformed to fulfil the 
assumptions of normality and homoskedasticity and to 
therefore allow the use of parametric testing. If this proved 
impossible the equivalent non-parametric test was used.
 All data used to produce Figs. 1, 3, 4, 5, 6, 7, 8 and 9 are 
shown in the Additional file 1.
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